Prevalence and Prognosis of Cerebrovascular Accidents and its Subtypes Among Patients with Systemic Lupus Erythematosus in Isfahan, Iran: A Hospital Clinic-based Study

Mohammad Saadatnia, Zahra Sayed-Bonakdar, Ghasem Mohammad-Sharifi, Amir Hossein Sarrami

ABSTRACT

Background: The aim of the present study was to determine the prevalence and prognosis of cerebrovascular accident (CVA) and its subtypes among Iranian patients with systemic lupus erythematosus (SLE).

Methods: In a cross-sectional study, medical records of 575 SLE patients were reviewed. The patients developing CVA in their course of disease were extracted. In these patients, data about demographic features, lupus antibodies, duration of the disease until CVA, CVA manifestation(s) and follow-up duration were gathered. In the next step, patients with any kinds of CVA were summoned to Neurology clinic to identify the grade of disability in each patient with CVA.

Results: We identified 38 patients with CVA of which 6 (15.8%) were men and 32 (84.2%) were women. The most common subtype of CVA was small vessels thrombosis (21.05%) among the study patients and hemiparesis was the most prevalent initial presentation (39.47%). In 11 (28.9%) patients, SLE was initiated with CVA and in 3 (7.9%) patients CVA had happened in the 1st year of SLE. Anti-phospholipid antibodies (APLA) were positive in 29 (76.3%) patients. Mean modified Rankin Scale in patient with positive and negative serology for APLA was 0.93 ± 1.11 and 0.22 ± 0.66 respectively (P = 0.006).

Conclusions: Our study shows that 6.6% of Iranian SLE patients have CVA during their course of the disease. Small vessels thrombosis is the most common CVA subtype and hemiparesis is the most prevalent initial presentation. Moreover, we showed that the prognosis of CVA in Iranian SLE patients is not unfavorable.

Keywords: Cerebrovascular accident, stroke, systemic lupus erythematosus

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown cause which can affect several parts of the body even central nervous system (CNS). Among CNS manifestations, cerebrovascular accident (CVA) is one
of the severe complications. Previous cohort studies revealed that 3-20% of SLE patients may experience an episode of CVA during their course of the disease.\textsuperscript{[4-6]} Data about differential features and various subtypes of CVA in Iranian SLE patients are lacking. In this study, we aimed to determine the prevalence and prognosis of CVA and its subtypes among Iranian SLE patients.

**METHODS**

**Patients and settings**

This study was a cross-sectional hospital clinic-based study that performed in Isfahan, Iran. During the period of 1 year, since February 2010-2011, SLE patients attending the Rheumatology Clinic of Alzahra Hospital (a tertiary referral center in Isfahan, Iran) enrolled in the study. Their medical documents have been reviewed and patients who had developed acute CVA include of ischemic attack, hemorrhagic attack, cerebral vasculitis and cerebral vein thrombosis in their course of disease were extracted. Drug-induced vasculitis, generalized vasculopathy, transverse myelitis and loss of consciousness due to metabolic disorders were causes of exclusion.

In patients who enrolled the study demographic data, SLE related clinical and laboratory findings and neurological symptoms in the disease duration were recorded.

**Diagnosis and assessment**

SLE was diagnosed according to the revised criteria which suggested by American College of Rheumatology at 1997.\textsuperscript{[7]} Stroke was diagnosed according to the World Health Organization definition.\textsuperscript{[8]}

“Trial of Org 10172 in Acute Stroke Treatment” (TOAST) classification system was used to denote different subtypes of CVA.\textsuperscript{[9]} Diagnosis was based on the clinical features and on data collected by brain imaging.

Inpatients with CVA, demographic features, history of hypertension, dyslipidemia and diabetes mellitus, anti-phospholipid antibodies (APLA), duration of the disease until CVA, CVA manifestation(s) and follow-up duration were extracted.

In the next step, patients with any kinds of CVA were summoned to neurology clinic to identify the grade of disability. The grade of disability of CVA determined for each patient through a precise neurological exam by a single expert neurologist using modified Rankin scale (MRS).\textsuperscript{[10]}

Imaging study of each patient (which was done at the time of hospitalization) was studied again and the subtype of CVA was confirmed by a single neurologist.

We used SPSS 20.0 software (IBM SPSS Statistics) for analysis of the data. The \( t \)-test was used as appropriate. Statistical significance was assumed at \( P \leq 0.05 \).

**RESULTS**

Of the total number 575 patients (64 men and 511 women) enrolled in the study, 38 were identified to have CVA. 6 (15.8%) were men and 32 (84.2%) were women. Their ages at the time of CVA ranged from 19 to 69 years, with the mean of 35.1 ± 1.2 years.

Small vessels thrombosis was the most common subtype, which includes eight patients (21.05%).

More detailed data are shown in Table 1. 12 (31.6%) patients had a history of hypertension; positive history of diabetes mellitus was present in two (5.7%) patients and seven (18.4%) had hyperlipidemia.

Duration of SLE before CVA in the study patients ranged from 0 to 16 years, with the mean of 4.25 ± 4.59 years. In 11 (28.9%) patients SLE was initiated with CVA and in three (7.9%) patients CVA was happened in the 1\textsuperscript{st} year of SLE. APLAs were positive in 29 (76.3%) patients.

<table>
<thead>
<tr>
<th>CVA subtype</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large vessels thrombosis</td>
<td>6</td>
<td>15.78</td>
</tr>
<tr>
<td>Small vessels thrombosis</td>
<td>8</td>
<td>21.05</td>
</tr>
<tr>
<td>Cardio emboli</td>
<td>3</td>
<td>7.90</td>
</tr>
<tr>
<td>Cerebral vasculitis</td>
<td>7</td>
<td>18.43</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>5</td>
<td>13.15</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>1</td>
<td>2.63</td>
</tr>
<tr>
<td>CVT</td>
<td>3</td>
<td>7.90</td>
</tr>
<tr>
<td>PRES</td>
<td>3</td>
<td>7.90</td>
</tr>
<tr>
<td>CVA secondary to hypercoagulable state</td>
<td>2</td>
<td>5.26</td>
</tr>
<tr>
<td>Total</td>
<td>38</td>
<td>100</td>
</tr>
</tbody>
</table>

CVA=Cerebrovascular accident, CVT=Cerebral venous thrombosis, PRES=Posterior reversible encephalopathy syndrome, SLE=Systemic lupus erythematosus
In fact, in 88.2% of all ischemic attacks (include of large vessels thrombosis, small vessels thrombosis and cardio emboli) APLAs were positive.

With the mean follow-up of 4.4 ± 3.4 years, mean MRS was 0.76 ± 1.12. In 24 patients, MRS at the last visit was zero. More detailed are shown in Table 2. In two patients, the CVA had recurred and in two patients transient ischemic attacks was recorded prior to CVA.

The most common CVA manifestation in our study was hemi paresis, which occurred in 15 (39.47%) patients. Detailed data about CVA initial presentations are shown in Table 3.

**DISCUSSION**

Previously, it has been demonstrated that age of SLE onset and sex ratio in Iranian patients are similar to those from other racial groups. Present study showed that the prevalence of CVA in Iranian SLE patients is 6.6%. This prevalence is also within the range that reported from other parts of the world.

Of the 38 CVA patients, in 11 cases CVA was the initial symptom of SLE. Futrell et al. implied that most SLE patients who develop CVA have their first CVA during the first 5 years of their disease.

**Table 2:** The comparison of MRS and SLE duration before CVA among CVA patients with positive and negative APLA

<table>
<thead>
<tr>
<th>Duration and MRS</th>
<th>Positive APLA (N=29)</th>
<th>Negative APLA (N=9)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of SLE before CVA (years)</td>
<td>3.36±3.97</td>
<td>7.11±5.51</td>
<td>0.215</td>
</tr>
<tr>
<td>Mean MRS of disability</td>
<td>0.93±1.11</td>
<td>0.22±0.66</td>
<td>0.006</td>
</tr>
</tbody>
</table>

Data are presented as mean±standard deviation. CVA=Cerebrovascular accident, APLA=Anti-phospholipid antibody, MRS=Modified rankin scale, SLE=Systemic lupus erythematosus

**Table 3:** Initial presentation of CVA among the study patients

<table>
<thead>
<tr>
<th>Initial presentation</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure</td>
<td>13</td>
<td>34.21</td>
</tr>
<tr>
<td>Hemi paresis</td>
<td>15</td>
<td>39.47</td>
</tr>
<tr>
<td>Brain stem involvement</td>
<td>6</td>
<td>15.78</td>
</tr>
<tr>
<td>Loss of consciousness</td>
<td>2</td>
<td>5.26</td>
</tr>
<tr>
<td>Headache</td>
<td>2</td>
<td>5.26</td>
</tr>
</tbody>
</table>

CVA=Cerebrovascular accident

In fact, the prevalence of CVA in Iranian SLE patients that we have identified is likely to be an underestimation of the true frequency. Second, due to positive history of some factors such as the highest rate is found during the 1st year. In fact, it seems that in some patients SLE has special tendency to involve cerebral vessels, which is not related to the duration of SLE, but the nature of SLE.

The current study implies that a large proportion of all acute CVAs in Iranian SLE patients are constituted by ischemic attacks. This fact may reflect the influence of APLA and other autoantibodies, premature atherosclerosis, small vessel vasculopathy, arterial and venous thrombosis, embolism and vessel spasm in SLE.

Although CVT, posterior reversible encephalopathy syndrome (PRES) and CVA secondary to hypercoagulable state are not in TOAST classification, but in that classification there is a category for "stroke of other determined etiology." We expanded the classification for more exact recognition of stroke subtypes in SLE patients.

Among our patients, we identified three cases of CVT. Two were positive for APLA. Our data showed that CVT is constituted 7.9% of CVAs in Iranian SLE patients, which is higher than the prevalence of CVT in the normal population.

We also identified three cases with PRES. There is no study about the rate of PRES in SLE patients. Although PRES is not one of the classic CVA subtypes, but as the mechanism of PRES is cerebral vasospasm and because of endothelium dysfunction in SLE patients, we report PRES as the cause of 7.9% of CVAs in Iranian SLE patients.

As following the average follow-up of 4.4 years, mean MRS of patients were less than 1, we may construe that if a patient with SLE survives CVA and his or her 5 year rehabilitation would not be unfavorable. This finding in Iranian SLE patients is differed from previous studies in this field. Significant relationship between APLA and MRS (P = 0.006) shows that in patients with negative serology for APLA, morbidity rate of CVA is even less.

Our study also has some limitations; this study was not hospital-based so we were unwitting about the mortality rate of CVA in SLE patients. Thus, the prevalence of CVA in Iranian SLE patients that we have identified is likely to be an underestimation of the true frequency.
hypertension, hyperlipidemia and diabetes mellitus in some stroke patients, it was favorable to operate proper statistical tests for eliminating their effects on the occurrence of stroke. However, as our recorded data about the presence of these factors in other non-stroke patients was not sufficient this step was not possible. Disease activity of SLE and the type of APLA (anti-cardiolipin antibody or lupus anticoagulant) at the time of stroke were absent in our medical records which might have a correlation with the stroke subtypes. However, the study showed positive APLA in SLE patients with stroke had more prevalence and was associated with a worse prognosis.

**CONCLUSIONS**

According to the significant prevalence of CVA among SLE patients, CVA prevention should start at the early phase of disease and be considered as an essential component of therapeutic strategies. Iranian SLE patients are susceptible for different CVA subtypes include ischemic and hemorrhagic events. Moreover, we showed that the prognosis of CVA in Iranian SLE patients is not unfavorable.

**ACKNOWLEDGMENTS**

This study was supported by a grant from Isfahan University of Medical Sciences (Grant No. 289305).

**REFERENCES**


***Source of Support:*** Isfahan University of Medical Sciences (Grant No. 289305), **Conflict of Interest:** None declared.